Cimaas logo Cimaas logo
  • About
    • Mission
    • CiMaas Team
    • Supervisory Board
    • Scientific Advisory Board
    • New therapeutic concepts
    • News archive
    • Careers
    • Collaborations
  • Technology
    • Technology
    • Adoptive NK cell therapy
    • Dendritic cell vaccine
    • Publications
  • Pipeline
  • Investors
  • General public
  • Contact
  • About
    • Mission
    • CiMaas Team
    • Supervisory Board
    • Scientific Advisory Board
    • New therapeutic concepts
    • News archive
    • Careers
    • Collaborations
  • Technology
    • Technology
    • Adoptive NK cell therapy
    • Dendritic cell vaccine
    • Publications
  • Pipeline
  • Investors
  • General public
  • Contact
Posts tagged:

lung cancer

Post

CiMaas receives RVO innovation credit for DC vaccine clinical trial

Cimaas has received an important stimulus from the Netherlands Enterprise Agency (RVO) for the development of a therapeutic dendritic cell (DC) vaccine against lung cancer. It concerns a loan of € 2.4 million. 

Post

Oncologie.nu publishes interview with CEO Gerard Bos

Dutch website Oncologie.nu has interviewed CiMaas’ Gerard Bos on the development of the dendritic cell vaccine for lung cancer.

  • Disclaimer
  • Contact
visual design by scicomvisuals.
  • About
  • Technology
  • Pipeline
  • General public